Physician profile
Robert D Mccroskey
NPI 1629064589
$3,553.83
in general payments reported to CMS, 2019-2025
18 companies · $20.19 in 2025
The $20.19 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,080 · 2021: $43.42 · 2022: $163 · 2024: $247 · 2025: $20.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $267.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,465.86 | 2019 | |
| Pfizer International LLC | $333.00 | 2019 | |
| Gilead Sciences, INC. | $203.96 | 2021-2024 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $124.97 | 2022 | |
| Astrazeneca Uk Limited | $94.68 | 2019 | |
| Abbvie INC. | $59.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.69 | 2019 | |
| Kyowa Kirin, INC. | $31.50 | 2021 | |
| Glaxosmithkline, LLC. | $30.20 | 2024 | Ojjaara |
| Daiichi Sankyo INC. | $24.80 | 2024 | Vanflyta |
| Verastem, INC. | $23.08 | 2019 | |
| Puma Biotechnology, INC. | $22.58 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $20.19 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $19.11 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.38 | 2019 | |
| Pfizer INC. | $13.63 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mccroskey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.